TRIV-573 for moderate to severe atopic dermatitis in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial will randomize adults with moderate to severe atopic dermatitis to receive five doses of TRIV-573 or placebo. The study lasts up to 40 weeks per participant, including screening up to 30 days. Researchers will monitor efficacy signals and safety outcomes to see if TRIV-573 can improve skin symptoms and overall disease burden compared with placebo.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Has Atopic Dermatitis.
* Has moderate to severe, active and symptomatic atopic dermatitis.

Exclusion Criteria:

* Severe or uncontrolled medical conditions.
* Use of prohibited medications within stated washout periods.

Where it's running

• Triveni Bio Site #15
  Fountain Valley, California, United States Recruiting
• Triveni Bio Site #4
  Los Angeles, California, United States Recruiting
• Triveni Bio Site #11
  Boca Raton, Florida, United States Recruiting
• Triveni Bio Site #7
  Miami, Florida, United States Recruiting
• Triveni Bio Site #3
  Miami, Florida, United States Recruiting
• Triveni Bio Site #2
  Indianapolis, Indiana, United States Recruiting

Study contacts

• Study coordinator: Triveni Bio, Inc
• Email: clinicaltrials@triveni.bio
• Phone: +1 (781) 472-2230

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Nocturnal ScratchSense ring: test of automatic scratch detection in adults with itchy skin

  This study tests whether the Replior ScratchSense ring can accurately detect and measure nighttime scratching in adults with itchy skin conditions.

  Recruiting Replior AB · Grenoble · NCT07909967

• ADBest TREAT Registry for adults with atopic dermatitis

  A registry in Germany is collecting real-world data from adults with atopic dermatitis to see how treatments are used and how the disease affects quality of life.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg · NCT07904546

• How lebrikizumab affects the skin microbiome and mycobiome in adults with atopic dermatitis

  This study looks at whether lebrikizumab changes the skin bacteria, fungi, and specifically Staphylococcus species, in adults with moderate-to-severe atopic dermatitis.

  Recruiting University Hospital Bispebjerg and Frederiksberg · Copenhagen · NCT07807228

• QX-4533 safety study in healthy volunteers and people with moderate-to-severe atopic dermatitis

  This study tests the safety and tolerability of QX-4533, given as a pill, in healthy adults and in patients with moderate-to-severe atopic dermatitis to see how the drug behaves in the body and what side effects may occur.

  Recruiting Phase 1 QuantX Biosciences US Inc. · Shanghai, Shanghai Municipality · NCT07800104

• Tilrekimig for moderate-to-severe eczema in teens and adults

  A 52-week study will test tilrekimig against dupilumab and a placebo to see if it helps people 12 and older with moderate-to-severe atopic dermatitis.

  Recruiting at 31 sites Phase 3 Pfizer · Birmingham, Alabama and 49 other locations · NCT07783425

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.